AstraZeneca leans on oncology and licensing to carry the post-Farxiga years

The technology

AstraZeneca's cancer pipeline covers several approaches. Sone-ve is an antibody-drug conjugate that targets CLDN18.2, and in the phase 3 CLARITY-Gastric01 trial it improved overall survival in second-line and later gastric cancer. SAFFRON paired Tagrisso with Orpathys, a MET inhibitor developed with HUTCHMED, and the combination improved progression-free and overall survival over chemotherapy in patients with MET-driven disease after Tagrisso. In July the company also licensed Zegfrovy, an oral inhibitor for EGFR exon 20 insertion lung cancer, from Dizal for $600 million upfront.

Imfinzi has also read out positively in VOLGA and NILE, two bladder cancer trials, and VOLGA is on the ESMO program for October 24. The non-cancer pipeline is less certain. Tozorakimab for COPD has been submitted in the EU and China, and Baxfendy for hypertension has FDA approval, according to the first-half report.

The odds

BIO, Informa and QLS data show that 57.8% of phase 3 programs reach a filing and 90.6% of filings are approved. Zegfrovy is already approved after platinum chemotherapy, and its first-line application is under review in the U.S. and China. SAFFRON and CLARITY-Gastric01 are the programs that sit between positive topline data and filing.

Neither readout comes with numbers. SAFFRON gave no hazard ratios, and CLARITY-Gastric01 gave none either. The latter also missed an overall-population progression-free survival goal, which regulators will weigh. The company's record this year is mixed: three phase 3 trials missed primary endpoints in the first half, including Wainua in ATTR-CM.

The money

First-half total revenue was $30.67 billion, up 9%. Oncology contributed $14.12 billion, up 18%, and BioPharmaceuticals $11.15 billion, down 1%. Core EPS rose 12% to $5.21. Net debt at June 30 was $26.9 billion, with $4.89 billion of cash. Reported R&D spending was $7.55 billion for the half, up 12%.

AstraZeneca reconfirmed 2026 guidance of mid-to-high single-digit revenue growth and low double-digit core EPS growth, and says it is on track for its $80 billion revenue ambition in 2030. It also raised its interim dividend by 3 cents to $1.06 per share. That leaves the company paying out cash while carrying net debt, a pattern that holds as long as oncology keeps growing at the rate it has this year.

The risks

Farxiga is the clearest one. It sold $4.00 billion in the half, down 5%, and the company cited its U.S. loss of exclusivity and Chinese procurement as headwinds. The BioPharmaceuticals division is shrinking while oncology grows.

Pipeline misses are the second, and the first-half report counts three phase 3 trials that failed their primary endpoints. The Wainua miss in ATTR-CM removes a heart-disease expansion that would have widened the drug, and the partners' release did not describe a follow-up trial. Imfinzi also failed in adjuvant liver cancer.

The third is leverage plus dependence on China-sourced assets. Two licenses in July carried a combined $800 million in upfront payments and up to $2.8 billion in milestones.

Our read

AstraZeneca is a growth company in oncology that is managing a decline in a big cardio-renal drug. The latest readouts are encouraging but incomplete, and the full numbers arrive at ESMO on October 24 and 25. Results for nine months follow on October 30. The balance sheet can carry the licensing strategy, but it leaves less room for a large acquisition if one of the late-stage programs falters.